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Background: Lynch syndrome (LS) is associated with germline mutations in DNA mismatch repair (MMR) genes.
The first “hit” to inactivate one allele of the predisposing MMR gene is present in every cell, contributing to
accelerated tumorigenesis. Less information is available of the nature, timing, and order of other molecular “hits”
required for tumor development. To this end, MMR protein expression and coordinated promoter methylation were
examined in colorectal specimens prospectively collected from LS mutation carriers (n = 55) during colonoscopy
surveillance (10/2011–5/2013), supplemented with retrospective specimens.
Results: Loss of MMR protein corresponding to the gene mutated in the germline increased with dysplasia, with
frequency of 0 % in normal mucosa, 50–68 % in low-grade dysplasia adenomas, and 100 % in high-grade dysplasia
adenomas and carcinomas. Promoter methylation as a putative “second hit” occurred in 1/56 (2 %) of tumors with
silenced MMR protein. A general hypermethylation tendency was evaluated by two gene sets, eight CpG island
methylator phenotype (CIMP) genes, and seven candidate tumor suppressor genes linked to colorectal carcinoma
(CRC). Hypermethylation followed the same trend as MMR protein loss and was present in some low-grade
dysplasia adenomas that still expressed MMR protein suggesting the absence of a “second hit.” To assess
prospectively collected normal mucosa for carcinogenic “fields,” the specimen donors were stratified according to
age at biopsy (50 years or below vs. above 50 years) and further according to the absence vs. presence of a
(previous or concurrent) diagnosis of CRC. In mutation carriers over 50 years old, two markers from the candidate
gene panel (SFRP1 and SLC5A8) revealed a significantly elevated average degree of methylation in individuals with
CRC diagnosis vs. those without.
Conclusions: Our findings emphasize the importance and early appearance of epigenetic alterations in
LS-associated tumorigenesis. The results serve early detection and assessment of progression of CRC.
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Table 1 Characteristics of sample series
Prospective
series
Retrospective
series
No. of individuals
or specimens
No. of individuals
or specimens
Lynch syndrome
• Individuals with mutation in
MLH1 39 (71 %) 33 (77 %)
MSH2 13 (24 %) 7 (16 %)
MSH6 3 (5 %) 3 (7 %)
Total 55 43
• Colorectal specimens
Normal colonic mucosa 55 24
Hyperplastic polyp 10 –
Low dysplasia adenoma 5 27
High dysplasia adenoma 3 13
Carcinoma 3 20
Total 76 84
Familial adenomatous polyposis
• Individuals with mutation in
APC 22 (100 %) –
• Colorectal specimens
Normal colonic mucosa 22 –
Adenoma (all dysplasia grades) 23 –
Carcinoma – –
Total 45 –
Note: three carcinomas, three low-grade dysplasia adenomas, and two
high-grade dysplasia adenomas were available as fresh frozen and FFPE samples
and were simultaneously included in both prospective and retrospective series
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Colorectal cancer (CRC) develops via multiple steps involv-
ing genetic and epigenetic changes. The majority of CRCs
are sporadic. In Lynch syndrome (LS), inherited defects of
the DNA mismatch repair (MMR) genes MLH1, MSH2,
MSH6, and PMS2 confer high lifetime risks of CRC and
extracolonic cancers [1]. Cancers arising in LS mutation
carriers as well as some 12 % of sporadic CRCs exhibit
microsatellite instability (MSI) [2]. Promoter methylation of
MLH1 was recognized as a primary cause for sporadic MSI
CRC [3, 4]. In LS, germline mutation combined with som-
atic mutations or loss of heterozygosity underlies biallelic
inactivation of MMR genes. MMR defects together with
other genetic and epigenetic changes accelerate neoplastic
transformation of the normal colonic epithelium [5].
Aberrant CpG island methylation affecting multiple
tumor suppressor genes is frequent in sporadic CRC and
colonic adenomas [6, 7], giving rise to a CpG island meth-
ylator phenotype (CIMP). CIMP tumors form a subtype
with distinct histology compared to tumors derived from
the traditional adenoma carcinoma sequence [8]. The
molecular basis of CIMP and its clinical implications are
only beginning to be explored [5, 9]. In hereditary CRC,
the importance of CIMP is largely unknown.
This investigation was undertaken to clarify the role of
CIMP and its time of appearance in colorectal adenoma-
carcinoma progression sequence in LS. LS mutation
carriers are enrolled in lifelong colonoscopy surveillance
with 2–3-year intervals [10], and we took advantage of
the regular surveillance to obtain consecutive specimens.
Furthermore, a previous mouse study implicated a
number of candidate genes in association with MLH1
mutation and diet [11], prompting us to evaluate the
respective genes as methylation targets in human LS.
Results
Study design
Biopsy specimens fresh frozen from different parts of the
colon and rectum, together with blood samples, were ob-
tained from 55 consecutive LS mutation carriers who
underwent regular colonoscopy screening or colectomy at
two Finnish hospitals during 10/2011–5/2013 (Table 1).
This prospective series was used to study DNA methylation
changes in normal colonic mucosa with respect to aging
and previously diagnosed cancer. As only a few individuals
developed colorectal lesions (mostly hyperplastic polyps)
during the 1.5-year interval, all archival tubular and villous
adenomas and carcinomas previously diagnosed in the
same individuals were gathered (retrospective series in
Table 1) and used to investigate DNA methylation changes
occurring in the adenoma carcinoma progression sequence.
Colonic and rectal biopsies from 22 familial adenomatous
polyposis (FAP) mutation carriers who participated in col-
onoscopy screening (Table 1) were studied for comparison.MMR status and analysis of MMR gene promoter
methylation as the “second hit”
To test if the predisposing MMR gene had undergone
somatic inactivation of the remaining wild-type allele,
colorectal specimens were evaluated for MMR protein
expression by immunohistochemical (IHC) analysis. All
adenomas with high-grade dysplasia and all carcinomas
from LS patients showed loss of MMR protein corre-
sponding to the gene mutated in the germline whereas
only 68 %, 67 % and 50 % of adenomas with low-grade
dysplasia showed loss of expression in MLH1, MSH2, and
MSH6 mutation carriers, respectively (Table 2). The differ-
ence (adenomas with low-grade dysplasia vs. adenomas
with high-grade dysplasia and adenomas with low-grade
dysplasia vs. carcinomas) was statistically significant for
MLH1-associated tumors. Overall, the results suggest that
silencing of the relevant MMR protein expression is a rela-
tively late event in LS tumorigenesis. MSI analysis with the
mononucleotide repeat markers BAT25 and BAT26 showed
that all adenomas and carcinomas with absent MMR pro-
tein were microsatellite unstable with one exception, an
Table 2 Proportion of decreased MMR protein expression in Lynch syndrome adenomas and carcinomas
Proportion (%) with decreased MMR protein corresponding to the gene mutated in germline
MLH1 p value vs.
normal colon
p value vs.
low dysplasia
MSH2 p value vs.
normal colon
p value vs.
low dysplasia
MSH6 p value vs.
normal colon
p value vs.
low dysplasia
Total p value vs.
normal colon
p value vs.
low dysplasia
Normal colon 0/33 (0 %) 0/7 (0 %) 0/3 (0 %) 0/43 (0 %)
Adenoma low
dysplasia
17/25 (68 %) <0.0001 4/6 (67 %) 0.021 1/2 (50 %) NS 22/33 (67 %) <0.0001
Adenoma high
dysplasia
13/13 (100 %) <0.0001 0.034 1/1 (100 %) NS NS – NS 14/14 (100 %) <0.0001 0.020
Carcinoma 12/12 (100 %) <0.0001 0.036 3/3 (100 %) 0.008 NS 5/5 (100 %) 0.018 NS 20/20 (100 %) <0.0001 0.003
NS, no statistical significance
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carrier. The low tumor cell percentage (20 %) in that par-
ticular sample was likely to explain stable microsatellites.
All eight low-grade dysplasia adenomas retaining MMR
protein expression were microsatellite stable.
Promoter methylation as a possible “second hit” was
assessed in tumors lacking MMR protein. Methylation of
MLH1 was mostly detected in the distal promoter (region
A [12]). This region was methylated in 30 %, 31 % and
60 % of adenomas with low-grade dysplasia, adenomas
with high-grade dysplasia and carcinomas, respectively
(Fig. 1). On the contrast, methylation of the proximal pro-
moter (region C), most commonly associated with MLH1
protein loss, was only observed in one adenoma having
high-grade dysplasia. No methylation was detected in
promoter regions of MSH2 or MSH6. Taken together,
promoter methylation constituted a putative “second hit”
in 1/56 (2 %) tumors with silenced MMR protein.
CIMP
To assess whether coordinated methylation of multiple
CpG islands that are normally unmethylated plays a role
in colorectal tumorigenesis, methylation-specific multi-
plex ligation-dependent probe amplification (MS-MLPA)Fig. 1 Frequency of hypermethylated CIMP markers in the LS retrospective
Hypermethylation thresholds were calculated according to stringency level
(two-sided p values), and the p values were adjusted for multiple compariswas used to study eight genes firmly associated with
CIMP (CACNA1G, IGF2, NEUROG1, RUNX3, SOCS1,
CDKN2A, MLH1, and CRABP1). The MS-MLPA CIMP
probe mix contains 3–6 probes for each CIMP marker
gene, and the average methylation dosage ratios (Dm)
obtained for each probe and type of specimen are given
in Additional file 1: Table S1. Hypermethylation in
tumor tissues was evaluated relative to probe-specific
thresholds derived from normal mucosa. The hyper-
methylation thresholds for the retrospective (FFPE)
series are given in Additional file 2: Table S2 and those
for the prospective (fresh frozen) series in the legend
of Additional file 3: Figure S1. A gene was considered
hypermethylated when at least one fourth (25 %) or
more of probe target sites were methylated [13].
The prospective LS series revealed increased methy-
lation in adenomas and carcinomas vs. normal colonic
mucosa for the CIMP markers IGF2, NEUROG1, and
CRABP1 (p values mostly non-significant due to small
numbers of specimens; Additional file 3: Figure S1A).
Hyperplastic polyps, too, showed frequent hypermethy-
lation with IGF2 and NEUROG1. LS vs. FAP-associated
adenomas and matching normal mucosa showed com-
parable frequencies of hypermethylation.series. Numerical values of percentages are given above each bar.
I. Pairwise comparisons were calculated by Fisher’s exact test
ons by Bonferroni correction
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with higher number of tumors available (Fig. 1). Adenomas
with high-grade dysplasia and carcinomas showed the high-
est frequencies of hypermethylation (defined with strin-
gency level I of Additional file 2: Table S2). The frequencies
of hypermethylation for IGF2 and NEUROG1 were signifi-
cantly increased in all tumor types when compared to nor-
mal colon. Notably, the difference was significant already in
adenomas with low-grade dysplasia (89 % vs. 21 %, p <
0.001, for IGF2 and 56 % vs. 8 %, p < 0.001, for NEUROG1).
Only carcinomas showed significantly elevated hyperme-
thylation frequencies forMLH1 and CRABP1.
As no consensus exists on how to score CIMP and no
single panel is superior to others [13], three different
marker panels were considered. Colorectal specimens
from the retrospective series were divided into CIMP(+)
or CIMP(−) categories by using the Ogino 5/8, Ogino 6/8,
and Weisenberger 3/5 panels (“Methods” section). Here,
stringency level II (Additional file 2: Table S2) was used to
calculate probe-specific thresholds to avoid hypermethyla-
tion in normal mucosa. The frequency of CIMP(+) speci-
mens increased from normal mucosa to adenomas with
low-grade dysplasia to adenomas with high-grade dyspla-
sia to carcinomas regardless of the marker system used
(Fig. 2). The Weisenberger panel yielded somewhat higher
CIMP(+) frequencies compared to the Ogino panels.
Accordingly, 15 %, 23 % and 50 % of the adenomas with
low-grade dysplasia, adenomas with high-grade dysplasia,
and carcinomas, respectively, were CIMP(+) when using
the Weisenberger 3/5 panel, compared to 7 %, 23 % and
40 % with the Ogino 5/8 criteria, and 4 %, 23 % and 25 %
with the Ogino 6/8 criteria (Fig. 2). Formal statistical sig-
nificance was reached in the normal mucosa vs. carcin-
omas comparison according to Ogino 5/8 (p = 0.006) and
Weisenberger 3/5 (p < 0.001) criteria and borderline signifi-
cance in the adenomas with low-grade dysplasia vs. carcin-
omas comparison according to Ogino 5/8 (p = 0.054)
criteria. CIMP(+) vs. CIMP(−) tumors were diagnosed at
similar average ages (48 vs. 49 years for adenomas and 49
vs. 48 years for carcinomas) excluding age as a possible
confounding factor in the analyses (see below).Methylation analysis of candidate genes
A custom MS-MLPA kit was designed to study methyla-
tion of seven candidate genes previously associated with
early colon oncogenesis in an experimental mouse
model (DKK1, SFRP1, SFRP2, SFRP5, CDH1, HOXD1,
and SLC5A8 (Additional file 4: Table S3) [11]. The aver-
age Dm obtained for each probe and type of specimen
are shown in Additional file 1: Table S1. Probe-specific
hypermethylation thresholds were determined as de-
scribed for CIMP markers (stringency level I), separately
for the retrospective series (Additional file 2: Table S2)and the prospective series (legend of Additional file 3:
Figure S1).
The prospective LS series indicated significantly higher
frequencies of hypermethylation for SFRP1 (95 %,
p = 0.006) and SFRP2 (67 %, p = 0.012) in carcinomas vs.
normal colonic mucosa (Additional file 3: Figure S1B).
Additionally, 50 % of hyperplastic polyps revealed hy-
permethylation for SFRP1 relative to normal mucosa
(p = 0.030). Hypermethylation frequencies in colonic
tissues were comparable in LS vs. FAP.
In the retrospective LS series, hypermethylation frequen-
cies for SFRP2 were significantly higher in all tumor types
when compared to normal mucosa (Fig. 3). Importantly,
this included adenomas with low-grade dysplasia already
(50 % vs. 13 %, p = 0.042). For SFRP1, significantly in-
creased frequencies of hypermethylation were only ob-
served in adenomas with high-grade dysplasia and
carcinomas (Fig. 3).
Correlation of candidate gene methylation with mRNA
expression in cancer cell lines
To evaluate functional significance of promoter methyla-
tion, MMR-deficient colorectal, endometrial, and ovarian
cancer cell lines (Additional file 5: Table S4) were treated
with the demethylating agent 5-aza-CdR and the histone
deacetylase inhibitor TSA, followed by RNA profiling on
microarrays. Consistent (1.8–7.2-fold) treatment-induced
upregulation of SFRP1 was seen in HCT15, HCT116, and
HEC59 analogous to LS-associated CRC and endometrial
cancer. SFRP2 was significantly upregulated (1.9-fold) in
HCT116. Upregulation was accompanied by reduced
promoter methylation by MS-MLPA.
When methylation (Dm) values were plotted against
mRNA expression in all studied cancer cell lines (treated
and untreated) and the corresponding normal tissues, a
significant inverse correlation was observed between SFRP1
(r= −0.688, p = 0.001) and SFRP2 (r = −0.657, p = 0.002)
mRNA expression and methylation (Additional file 6:
Figure S2). Moreover, SFRP1 and SFRP2 expressions were
significantly lower in the untreated cancer cell lines com-
pared to the corresponding normal controls (data not
shown). Our data suggest that DNA methylation plays a sig-
nificant role in the expressional regulation of these genes.
Hypermethylation of CIMP and candidate genes vs.
expressional status of MMR proteins
Eleven adenomas with low-grade dysplasia retained
MMR protein expression (Table 2) suggesting that the
second hit to inactivate the responsible MMR gene had
not yet occurred. DNA was available for eight such
adenomas, and 3/8, 4/8, 6/8, and 2/8 revealed hyper-
methylation of IGF2, NEUROG1, SFRP1, and SFRP2,
respectively. The hypermethylation frequencies were es-
sentially comparable to those in low-grade dysplasia
Fig. 2 Frequency of CIMP(+) specimen calculated by three different criteria. Numerical values of percentages are given above each bar.
Hypermethylation thresholds were calculated according to stringency level II. Pairwise comparisons were calculated by Fisher’s exact test
(two-sided p values), and the p values were adjusted for multiple comparisons by Bonferroni correction
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and 10/18 for the respective loci). The results suggest that
hypermethylation of the investigated genes can occur prior
to somatic inactivation of the predisposing MMR gene.
Effect of age at biopsy on normal colonic tissue
methylation
Since DNA methylation tends to increase with age [14],
the level of methylation in each prospectively collected
colorectal mucosa specimen was evaluated against the
chronological age of the individual at the time of biopsy.
A moderate-to-strong positive correlation was detected
between age at biopsy and normal colonic mucosa Dm
values corresponding to IGF2 probes I (r = 0.694,
p < 0.0001), II (r = 0.726, p < 0.0001), and III (r = 0.742,
p < 0.0001) and NEUROG1 probes I (r = 0.566, p < 0.0001),III (r = 0.703, p < 0.0001), and IV (r = 0.655, p < 0.0001)
(Additional file 7: Figure 3SA–B). Additionally, moderate
correlation between age at biopsy and SFRP1 (r = 0.554,
p < 0.0001), SFRP2 (r = 0.550, p < 0.0001), and SLC5A8
(r= 0.554, p < 0.0001) methylation was observed in normal
colonic mucosa (Additional file 7: Figure S3C). This
indicates that aging itself increases methylation of the
CIMP markers in the histologically normal mucosa. No
age-related correlation was observed for MLH1 region C
methylation.
Analysis of field defects in histologically normal
colonic mucosa
To investigate if aberrant DNA methylation might form
carcinogenic “fields” in the histologically normal mucosa,
colonic mucosa biopsies of the prospective LS series were
Fig. 3 Frequency of hypermethylated candidate genes in the LS retrospective series. Numerical values of percentages are given above each bar.
Hypermethylation thresholds were calculated according to stringency level I. Pairwise comparisons were calculated by Fisher’s exact test (two-sided
p values), and the p values were adjusted for multiple comparisons by Bonferroni correction
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candidate genes. The individuals were divided into four
groups depending on age at biopsy and absence vs.
presence of (previous or concurrent) CRC (groups 1–4).
The first two groups included mutation carriers 50 years
old and below and consisted of 22 individuals without
CRC (group 1) and 6 individuals with CRC (group 2). The
remaining two groups included mutation carriers above
50 years and consisted of 17 individuals without CRC
(group 3) and 10 individuals with CRC (group 4). The
interval between CRC diagnosis and time of biopsy was
5.1 years (range 0–11.5) in group 2 and 5.5 years (range
0–12.4) in group 4. Average age at biopsy was comparable
in group 1 (35, range 26–50) vs. group 2 (43, range
39–48) and in group 3 (61, range 51–75) vs. group 4
(63, range 51–74), excluding the age effect as a possible
confounder in the respective comparisons.
When the effect of CRC on CIMP marker methyla-
tion was examined within the age groups (≤50 andabove 50), no significant differences were observed (Add-
itional file 8: Figure S4). However, age effect was evident
from comparisons of the “under 50, no CRC” with the
“over 50, no CRC” groups and “under 50, CRC” with the
“over 50, CRC” groups, which revealed significant in-
creases in methylation for several IGF2 and NEUROG1
probes (Additional file 8: Figure S4).
The candidate genes, too, showed an age effect, but
despite it, significant increases in methylation were ob-
served for SFRP1 (p < 0.0001) and SLC5A8 (p = 0.007)
in the “over 50 group,” when stratified by the presence
vs. absence of previously diagnosed CRC (Fig. 4). More-
over, our results from duplicate MS-MLPA assays
(“Methods” section) as well as from dilution experi-
ments (Additional file 9: Figure S5) showed that the
observed changes in methylation were unlikely to be
explained by technical variation or other similar rea-
sons. Thus, our finding may indicate a potential field
defect in normal mucosa.
Fig. 4 Effect of aging and previously diagnosed CRC on SFRP1 and SLC5A8 normal colonic mucosa Dm values. Study groups: patients ≤50 years
without (n = 22) and with (n = 6) a CRC diagnosis, and patients >50 years without (n = 17) and with (n = 10) a CRC diagnosis. Statistical testing
was performed with one-way ANOVA and Tukey’s post hoc test or Kruskal-Wallis one-way ANOVA
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Studies on sporadic CRC have demonstrated that promoter
hypermethylation can act as an alternative mechanism to
mutations, having a causal role in colorectal tumorigenesis
[5, 3]. Promoter methylation can be detected in CRC-
associated normal colonic mucosa and aberrant crypt foci
(ACF), the earliest identifiable neoplastic lesions of the
colon [15, 16]. Aging increases genomic DNA methylation
[14] and is therefore particularly relevant to sporadic CRC
which develops two to three decades later than hereditary
CRC. We utilized unique features of LS, including in-
creased tumor incidence and the availability of multiple
specimens per individual (normal mucosa, adenoma,
and carcinoma, taken at different time points), to gain
insights into the role of DNA methylation alterations in
hereditary CRC.
Loss of MMR protein corresponding to the predisposing
MMR gene increased with the degree of dysplasia (Table 2),
in agreement with results from a smaller series of screen-
detected LS-adenomas [17]. In addition, we demonstrate
that inactivation ofMLH1 by somatic methylation can con-
stitute a “second hit” in LS-associated tumorigenesis. The
method of methylation analysis (notably, the ability for
quantification of methylation) and the particular region(s)
of MMR gene promoters evaluated are important factors
to take into account in “second hit” analyses. While one
previous study [18] detected MLH1 methylation in 10/18
(56 %) of LS-adenomas by methylation-specific PCR,
which is not a quantitative method, our frequency (1/30,
3 %, for region C methylation in adenomas with silenced
MLH1 protein) complies with other quantitative studies
for the same region suggesting that in a small but definite
proportion (2–15 %) of tumors from LS patients the
wild-type allele is inactivated by MLH1 promoter hyper-
methylation [19–22]. Hypermethylation of region A ofMLH1 was relatively common (up to 60 %) in the LS sam-
ples (Fig. 1). Methylation of region A correlates with age
and does not silence gene expression, whereas methyla-
tion of region C (located closely upstream to the tran-
scription start site) correlates with gene silencing [12, 21,
23]. Moreover, the single adenoma with MLH1 promoter
methylation in region C in our investigation was CIMP(+)
by all three criteria tested, supporting previous evidence
of MMR gene methylation as the “second hit” being asso-
ciated with a more general CIMP in the tumors [19, 24].
The fact that almost half of the low-grade dysplasia ad-
enomas retained MMR protein expression suggests that
somatic inactivation of the wild-type allele may not always
precede polyp formation, consistent with Yurgelun et al.
[25]. In such cases, the existence of other somatic driver
events has been hypothesized [26]. Moreover, non-
tumorous mucosa from resections for intestinal cancer re-
vealed a frequent occurrence of MMR-deficient crypt foci
in LS mutation carriers, which contrasts with the low
number of adenomas and carcinomas becoming clinically
manifested and underlines the necessity of other tumori-
genic events before or after MMR gene inactivation [27].
DNA methylation changes are excellent candidates for
such events. The exact step at which the most abundant
or important DNA methylation changes may occur re-
mains unsettled. In the sporadic setting, a number of stud-
ies conclude that most alterations disrupting the normal
patterns of DNA methylation occur in precursor lesions
(ACF and polyps) rather than at more advanced stages
(carcinoma and metastasis) [28]. On the other hand, Beggs
et al. [7] detected the bulk of promoter hypermethylation
in the transition from adenoma to carcinoma, rather than
from normal tissue to adenoma. Ibrahim et al. [29] found
that DNA methylation changes take place sequentially at
specific transition points involving RUNX3 in normal
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tic polyps, SFRP2 and IGF2-DMR0 in adenomatous
polyps, and CDKN2A and MLH1 in the adenocarcinoma
stage. We chose to use previously established CIMP
markers and panels and found that CpG island methyla-
tion in LS adenomas and carcinomas increases with dys-
plasia (Figs. 1 and 2). Among the individual markers, the
frequency of specimens with hypermethylation of IGF2
and NEUROG1 was significantly increased in adenomas
with low-grade dysplasia already (Fig. 1), including some
with the predisposing MMR gene not silenced, yet, indi-
cating that methylation of IGF2 and NEUROG1 may pro-
vide a marker of early colon oncogenesis.
In sporadic colorectal tumors, MMR deficiency is
mainly proposed to serve cancer progression rather than
initiation [30]. Moreover, analysis of microdissected glands
revealed significant heterogeneity for MSI and promoter
methylation of MMR genes within individual polyps [31].
Our IHC and MSI results (Table 2), like those by Yurgelun
et al. [25], suggest the possibility that some LS adenomas
might be initiated by mechanisms other than MMR defi-
ciency and that the MMR and non-MMR pathways may
converge in later stages (adenomas with high-grade dys-
plasia and carcinomas). CIMP and candidate genes were
often hypermethylated in low-grade dysplasia adenomas
from our series regardless of MMR status of the tumors;
thus, aberrant methylation might be among the earliest
events in colorectal tumors developing in MMR gene
mutation carriers.
Apart from adenomatous polyps that are viewed as pre-
cursors of CRC, LS mutation carriers may also exhibit
polyps that develop along the serrated pathway, including
hyperplastic polyps [32]. Hyperplastic polyps are tradition-
ally considered to be non-neoplastic, lacking potential for
malignant progression [33]. The latter view is supported by
observations of a virtual absence of MMR defects in hyper-
plastic polyps from LS mutation carriers [25, 34]. A gland-
level analysis of hyperplastic polyps from sporadic cases
has shown frequent MSI and methylation aberrations, and
the possibility that such polyps might be precursors to MSI
CRC cannot be ruled out [31]. In light of the findings de-
scribed above, the frequent hypermethylation we observed
for the markers from the CIMP panel (Additional file 3:
Figure S1A) and candidate gene panel (Additional file 3:
Figure S1B) in hyperplastic polyps from LS mutation
carriers is interesting and warrants further studies to
evaluate the significance of such methylation events in
tumorigenesis.
Specific dietary compounds are known to act as im-
portant modifiers of the methylation patterns of the
colon, and DNA methylation of the intestinal mucosa
can thus link nutrition to cancer [35]. Here, we report
significantly increased hypermethylation frequencies for
two secreted frizzled-related proteins, SFRP1 and SFRP2,in LS-associated adenomas and carcinomas when com-
pared to normal colon (Fig. 3). These genes emerged
from our previous dietary intervention study on the
Mlh1 mouse model [11]. In the normal colon epithelial
cells, SFRPs function as Wnt signaling antagonists and
compete with Wnt proteins for binding to their receptor,
frizzled. Transcriptional silencing of these genes through
promoter hypermethylation (epigenetic gatekeeper) acti-
vates the APC protein complex which further promotes
cell proliferation and ACF formation [36]. Interestingly,
hypermethylation of these genes with concomitant
reduction in gene expression was reported to apply to
both CIMP-high and non-CIMP tumors, which indicates
that aberrant methylation of these genes may occur in
colorectal tumors irrespective of their subtype [37].
Field defects are clonal abnormalities in the epithelial
gene expression that precede cancer development and
predispose to it, occasionally causing the simultaneous
occurrence of multiple tumors within a field [38]. Age-
related DNA methylation changes have been proposed
as potential sources of field defects in the colon [16, 14].
Observations that DNA methylation in normal mucosa
may associate with pathway-specific susceptibility to
CRC [39, 40] and that synchronous cancer pairs share
epigenetic features such as CIMP and LINE-1 methyla-
tion status [41] support the existence of epigenetic field
defects in CRC development. In our investigation, muta-
tion carriers over 50 years old with a previous CRC diag-
nosis showed a significantly elevated average degree of
methylation of SFRP1 and SLC5A8 vs. cancer-free indi-
viduals of a comparable age. Differences between the
two groups of mucosa were small though statistically
significant. SFRP1 was discussed above; SLC5A8 encodes
a sodium transporter that directly influences the absorp-
tion of short-chain fatty acids (e.g., butyrate, a histone
deacetylase inhibitor) from the apical membrane of the
intestinal tract into the colon [42] and is frequently
silenced in ACF and CRC by promoter methylation [43].
Our findings are consistent with a recent epigenome-
wide study by Luo et al. who identified 65 loci with
higher methylation in (sporadic) CRC-associated mucosa
vs. colon mucosa from cancer-free individuals [44].
Conclusions
We show that increased DNA methylation of CIMP
markers and candidate gene loci accompanies tumor pro-
gression in LS. Methylation alterations may form carcino-
genic fields in histologically normal mucosa and occur in
adenomas at a stage where MMR protein expression is still
intact. When affecting the predisposing MMR gene, pro-
moter methylation can constitute the somatic “second hit”.
Our results provide new insights into the multistep colo-
rectal tumorigenesis in LS and CRC in general [29, 36, 43].
The findings also pinpoint potential markers for early
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tered methylation at such marker loci may help identify in-
dividuals prone to develop CRC through CIMP who might
benefit from demethylating agents for chemoprevention or
treatment [45].
Methods
Patient samples
CRC families represented the nationwide Hereditary
Colorectal Cancer Registry of Finland. Colorectal fresh
frozen biopsies (prospective series, Table 1) were gathered
from LS and FAP patients during colonoscopy screenings
and colectomies performed at the Helsinki University
Central Hospital and Jyväskylä Central Hospital during
10/2011–5/2013. Normal mucosa biopsies were collected
from one to four distinct colonic regions. In addition,
blood was drawn to provide another source of normal
cells for comparison. Forty-three individuals from the
prospective series also contributed archival specimens
(retrospective series, Table 1; predisposing MMR gene
mutations specified in Additional file 10: Table S5). The
histology of adenomas and carcinomas was verified by one
of the authors (A.R). Carcinoma sections for DNA ex-
tractions contained 30–80 % tumor epithelium (average
50 %). The Institutional Ethics Board of Central Finland
Health Care District approved the collection of biopsies
during surveillance (K-S shp Dnro 10U/2011). The
National Authority for Medicolegal Affairs (Dnro 1272/
04/044/07) approved the collection of archival specimens.
Immunohistochemistry (IHC) for MMR protein expression
IHC was performed by standard procedures [46] with
the following primary antibodies: MLH1 (clone ES05;
75 mg/l; Dako North America, Inc. CA), MSH2 (clone
G219-1129; 0.5 mg/ml; BD Pharmingen), MSH6 (clone
EP49, AC00-47, Epitomics, Burlingame, CA), and PMS2
(clone EPR3947, 0.324 mg/ml, Abcam, Cambridge, UK).
Negative cancer cell immunostaining was interpreted to
indicate inactivation of the respective MMR gene.
Microsatellite instability (MSI) analysis
MSI analysis was based on the mononucleotide repeat
markers BAT25 and BAT26, which are sensitive and
specific indicators of the MSI-high phenotype [47, 48].
Tumors with unstable BAT25 or BAT26 were considered
to have MSI, whereas those with normal BAT25 and
BAT26 were microsatellite-stable.
Methylation-specific multiplex ligation-dependent probe
amplification (MS-MLPA) for methylation analysis
MS-MLPA probes contain a recognition sequence
(GCGC) for the methylation-sensitive endonuclease HhaI,
and methylated template DNA generates a signal peak
[49]. MS-MLPA was performed according to themanufacturer’s instructions [50]. The methylation dosage
ratios (Dm) were calculated separately for each normal
mucosa and tumor sample (Additional file 1: Table S1) as
described [51]. The Dm value of 0.15 or above (corre-
sponding to 15 % of methylated DNA) was treated as the
conservative technical threshold for methylation detection
[49]. Since the baseline level for methylation in normal tis-
sue may vary between probes (Additional file 1: Table S1),
normal mucosa specimens were used to determine thresh-
olds for hypermethylation in tumor tissues (Additional
file 2: Table S2). Dm values in each tumor were compared
to these thresholds to determine whether or not the
tumor was hypermethylated at the respective locus. The
results from individual tumors were then combined to
calculate the hypermethylation frequency for each tumor
type. The hypermethylation threshold (separate for fresh
frozen and archival tissue-derived DNA) was defined as
the mean Dm in normal mucosa plus 1 standard deviation
(stringency level I) or 2 standard deviations (stringency
level II) with the purpose to achieve an optimal discrimin-
ation between normal and tumor tissues. Stringency level
I was used in all contexts except for classification of tissue
specimens into CIMP(+) and CIMP(−) categories where
stringency level II provided a better distinction (Fig. 2). In
the prospective series, an average Dm value incorporating
1–4 colorectal regions was calculated to describe the
normal mucosa Dm of each individual.
MS-MLPA was found to be highly reproducible (an
average difference of Dm = 0.029 was observed between
288 replicate measurements) and sensitive (even 5 %
methylation could be reliably detected in most cases;
Additional file 9: Figure S5).MMR gene promoter methylation
For studies of the “second hit,” the methylation status of
MMR genes was analyzed by SALSA MLPA probemix
ME011 (MRC Holland, Amsterdam, The Netherlands).
Analyzed MLH1 promoter regions corresponded to
regions A, B, and C as described by Deng et al. [12].CpG island methylator phenotype (CIMP)
Promoter methylation of CACNA1G, IGF2, NEUROG1,
RUNX3, SOCS1, CDKN2A, MLH1, and CRABP1 was stu-
died by SALSA MLPA probemix ME042 (MRC Holland,
Amsterdam, The Netherlands). The probemix contains
3–6 probes for each CIMP marker gene. A gene was
considered methylated when one fourth (25 %) or more
probes were methylated [13]. Two alternative marker
panels were utilized to classify colorectal tumors as
CIMP(+) or CIMP(−). The Weisenberger panel [52, 53] in-
cludes five genes (CACNA1G, SOCS1, RUNX3, IGF2, and
NEUROG1), at least three of which should be methylated
for CIMP(+) [13]. The Ogino panel includes three
Valo et al. Clinical Epigenetics  (2015) 7:71 Page 11 of 13additional genes (CDKN2A, MLH1, and CRABP1) [52,
53], and five or more methylated genes out of eight
(Ogino 5/8, CIMP-low) or six or more methylated
genes out of eigth (Ogino 6/8, CIMP-high) were
regarded to indicate CIMP(+).Custom MS-MLPA for methylation analysis of candidate genes
To study promoter methylation of DKK1, SFRP1, SFRP2,
SFRP5, CDH1, HOXD1, and SLC5A8 [11], a custom
MS-MLPA assay was designed. CpG islands (CGI) were
identified by EMBOSS CpGplot [54] and CpG Island
Searcher [55]. DNAs from cancer cell lines and normal
tissues were bisulfite sequenced (with primers specified
in Additional file 4: Table S3A) to determine the methy-
lation statuses of the CpG sites within the CGIs. Custom
MS-MLPA probes were designed to target GCGC sites
(Additional file 4: Table S3B). Salsa MLPA P300-A2
Human DNA Reference-2 (MRC Holland, Amsterdam,
The Netherlands) was added to the custom designed
MS-MLPA probe mix. The custom assay was optimized
against bisulfite sequencing as described [56], resulting
in the conservative technical threshold of Dm ≥ 0.15 for
methylation detection.
Epigenetic drug treatments and analysis of genome-wide
mRNA expression
Cancer cell lines (Additional file 5: Table S4) were
treated with epigenetic drugs and RNA expression was
profiled on Affymetrix Human Genome U133 Plus 2.0
GeneChip® microarrays (Affymetrix, Santa Clara, CA) as
described [56]. Normal tissue DNA and RNA were
purchased from Amsbio (Abingdon, UK). Microarray
data were analyzed by GeneSpring GX software, version
12 (Agilent Technologies, Santa Clara, CA) using RMA
normalization. Statistically significant gene expression
changes were identified by moderated t test combined
with the Benjamini and Hochberg correction for mul-
tiple testing and by using filters based on p value cutoff
of 0.05 and fold change cutoff of +/−1.5. The mRNA
expression profiling data have been submitted to GEO
(accession number: GSE58058).
Statistical analysis
Statistical analysis of methylation data was performed
using the SPSS software, version 20.0 (IBM SPSS Inc.
Chicago, IL, USA). Frequency of methylated target sites
in each type of tissue specimen was calculated separately
for each gene using the probe-specific threshold values.
Two-sided p values were calculated for each pairwise
comparison by Fisher’s exact test and adjusted for mul-
tiple comparisons by Bonferroni correction. Pearson
product-moment correlation coefficient (r) was used to
study the correlation of methylation and expression andthe association between age at biopsy and methylation in
normal colonic mucosa (individual average normal colon
Dm values). Statistical significance of methylation differ-
ences between groups studied for field defects was tested
by one-way ANOVA, and Tukey’s post hoc test was used
for pairwise comparisons. Alternatively, the non-para
metric test Kruskal-Wallis one-way ANOVA (k samples,
pairwise comparisons) was utilized for series not nor-
mally distributed. Homogeneity of variances was tested
by Levene’s test and normality by Shapiro-Wilk test.
P values <0.05 were considered significant.
Additional files
Additional file 1: Table S1. Average methylation dosage ratios (Dm)
and standard deviations for normal colonic mucosa and each tumor type.
Additional file 2: Table S2. Threshold values for hypermethylation at
each gene locus in the Lynch syndrome retrospective series calculated
based on normal colonic mucosa specimens.
Additional file 3: Figure S1. Frequency of hypermethylated samples in
the LS and FAP prospective series.
Additional file 4: Table S3. (A) Bisulfite primer sequences and
(B) MS-MLPA probe design for candidate gene panel.
Additional file 5: Table S4. Cell line characteristics.
Additional file 6: Figure S2. Correlation between SFRP1 and SFRP2
mRNA expression and methylation.
Additional file 7: Figure S3. Correlation of age and normal colonic
mucosa methylation. (A) IGF2 probes I, II, and III. (B) NEUROG1 probes I, III,
and IV. (C) SFRP1, SFRP2, and SLC5A8.
Additional file 8: Figure S4. Effect of aging and previously diagnosed
CRC on normal colonic mucosa methylation. (A) IGF2 (probes I–III).
(B) NEUROG1 (probes I, III, IV, and VI).
Additional file 9: Figure S5. MS-MLPA sensitivity for (A) CIMP and (B)
candidate gene panel. Results obtained with a gradient of decreasing
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can be reliably detected.
Additional file 10: Table S5. Germline mutation specifications for
patients (retrospective series).
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